Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884)

Berthe M P Aleman, Théodore Girinsky, Richard W M Van Der Maazen, Simon Strijk, Paul Meijnders, Roberto Bortolus, Manouk J J Olofsen-Van Acht, Marnix L M Lybeert, Yolande Lievens, Houchingue Eghbali, Evert M. Noordijk, Radka Tomšič, Jacobus H. Meerwaldt, Philip M P Poortmans, Wilma G J M Smit, Antonella Pinna, Michel Henry-Amar, John M M Raemaekers

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate the impact of the quality of involved-field radiotherapy (IFRT) on clinical outcome in patients with advanced Hodgkin's lymphoma (HL) in complete remission (CR) after six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone-doxorubicin, bleomycin, and vinblastine (MOPP-ABV) chemotherapy. Methods and Materials: A retrospective review of clinical and radiologic data, radiation charts, simulator films, and megavoltage (MV) photographs was performed. IFRT consisted of 24 Gy to all initially involved nodal areas and 16-24 Gy to all initially involved extranodal sites. Major violations were defined as no or only partial irradiation of an originally involved area, or a total dose

Original languageEnglish
Pages (from-to)1184-1190
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume63
Issue number4
DOIs
Publication statusPublished - Nov 15 2005

Keywords

  • Advanced Hodgkin's lymphoma
  • Combined modality treatment
  • Quality assurance
  • Quality control
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Fingerprint Dive into the research topics of 'Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884)'. Together they form a unique fingerprint.

Cite this